Abstract: A composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.

Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Derivative, and methods of using the Cyclic Phosphate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

Abstract: The invention relates to thiazolopyridine derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.

Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS PS-FFS, SA-HB-FFS, polymer stabilised SA-HB-FFS, positive VA or positive PS-VA type.

Abstract: The invention relates to a medium comprising one or more compounds of formula I, R11-A11-A12-(CH2)s-A13-A14-R12??I in a concentration of up to 30% or less, and one or more compounds of formula II, R21-A21-A22-(A23)u-Z21—(CH2)t—Z22-A24-A25-A26-R22??II in a concentration of 10% or more, wherein R11 to R22, A11 to A26, Z21, Z22, s, t, and u have one of the meanings as given in claim 1, to a method of production of such a media, to the use of such media in liquid crystal devices, in particular in flexoelectric liquid crystal devices, and to a flexoelectric liquid crystal device comprising a medium according to the present invention.

Abstract: The present invention relates to stable catalyst ink formulations comprising am electrospinning polymer selected from halogen-comprising polymers. The present invention further relates to electrospinning of such ink formulation, to the so-obtained electrospun fibrous mat as well as to articles comprising such electrospun fibrous mat.

Abstract: A fluid transfer device comprising a first reservoir (1) having a predetermined sub-ambient pressure and volume and a presealed opening (1a), a second reservoir (2) containing a predetermined volume of a fluid (M) and having a presealed opening (2a), and a chamber (3) having an internal space (6) and an inlet (4) to the space (6) adapted to be connected to the opening (2a) of the second reservoir (2) and an outlet (5) from the space (6) adapted to be connected to the opening (1a) of the first reservoir (1).

Abstract: The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

Abstract: The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.

Abstract: The present invention relates to a photosensitive composition, and a color conversion film. The present invention further relates to a use of the photosensitive composition in a color conversion film fabrication process, and to a use of the color conversion film in an optical device. The invention further more relates to an optical device comprising the color conversion film and method for preparing the color conversion film and the optical device.

Abstract: Disclosed are pigment powders containing only coated BiOCl flakes, which flakes area) BiOCl flakes having a coating containing yellow iron oxide Fe2O3*xH2O, optionally a colorant, optionally an adjuvant, and optionally SiO2, b) BiOCl flakes having a coating containing SiO2, optionally a colorant, and optionally an adjuvant, c) BiOCl flakes having a coating containing a colorant, SiO2, optionally yellow iron oxide Fe2O3*xH2O, and optionally an adjuvant, or d) BiOCl flakes having a coating containing Fe3O4 and optionally SiO2, to a process for the preparation of the pigment powders, and to the use thereof especially in cosmetic formulations.

Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.

Abstract: The present invention relates to a method of reducing ODF mura in liquid crystal (LC) displays of the polymer sustained alignment (PSA) type and to PSA LC displays made by this method.

Abstract: The present invention relates to liquid-crystalline media comprising one or more compounds of formula T and one or more compounds selected from the group of compounds of formulae I, II and III, in which the parameters have the meaning indicated in Claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.

Abstract: The present invention relates to methods for the recombinant expression of Chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes Chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of Chlamydia infection and/or the effects thereof.

Abstract: The present disclosure relates to the field of anti-counterfeit protection of products. Specifically, the disclosure is directed to a composite security marking for a physical object, in particular to an anti-counterfeit product marking. In particular, without limitation, such composite security marking can be used in connection with or can form a component of a multi-component security system, in particular of an anti-counterfeit protection system, which is also disclosed herein as part of an overall solution for anti-counterfeit protection. The composite security marking comprises a physical unclonable function, PUF, and a representation of a digital signature or of a pointer indicating a location where said digital signature can be accessed. The digital signature digitally signs a hash value resulting from application of a predetermined cryptographic hash function to data representing a response generated by the PUF in reaction to a challenge of a predetermined challenge-response authentication scheme.

Abstract: The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.

Abstract: Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.